← Back to Search

EHR Interface to Reduce Hydroxychloroquine Dosage for Rheumatic Diseases

N/A

Waitlist Available

Led By Jinoos Yazdany, MD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post intervention: 3 years

Awards & highlights

Study Summary

This trial is looking at whether an electronic interface for prescribing hydroxychloroquine (HCQ) can reduce the number of people prescribed the drug above current guidelines. HCQ is a drug that can help regulate the immune system, but long-term use can lead to irreversible damage to the retina. The American Academy of Ophthalmology has guidelines on how much HCQ people should take based on their weight, and when to screen for retinal toxicity. Many people still receive too high of a dose of HCQ, so this trial is testing whether the new interface can help reduce that.

Who is the study for?

This trial is for healthcare providers in rheumatology and dermatology clinics who have prescribed hydroxychloroquine (HCQ) within the last year. Providers not currently active in these clinics cannot participate.Check my eligibility

What is being tested?

The study tests a new e-prescribing interface designed to help clinicians adhere to guidelines for HCQ dosing, aiming to reduce overprescription and prevent retinal toxicity from long-term use of high doses.See study design

What are the potential side effects?

While this trial focuses on reducing dosage through an e-prescribing system rather than direct patient effects, excessive HCQ can lead to irreversible eye damage.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ post intervention: 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~post intervention: 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and post intervention: 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Prevalence of dosage above guidelines: 5.0 mg/kg (2016)

Prevalence of dosage above guidelines: 6.5 mg/kg (2011)

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: New eRX InterfaceExperimental Treatment1 Intervention

Providers assigned to the intervention arm will be presented with a new eRX interface upon writing new prescriptions for hydroxychloroquine in the EHR.

Group II: Standard InterfaceActive Control1 Intervention

Providers assigned to the no intervention arm will be presented with the usual ordering interface when prescribing new prescriptions for hydroxychloroquine in the EHR.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor

2,500 Previous Clinical Trials

15,236,406 Total Patients Enrolled

1 Trials studying Rheumatic Diseases

652 Patients Enrolled for Rheumatic Diseases

Jinoos Yazdany, MDPrincipal InvestigatorUniversity of California, San Francisco

Media Library

New e-prescribing interface Clinical Trial Eligibility Overview. Trial Name: NCT04310462 — N/A

Rheumatic Diseases Research Study Groups: New eRX Interface, Standard Interface

Rheumatic Diseases Clinical Trial 2023: New e-prescribing interface Highlights & Side Effects. Trial Name: NCT04310462 — N/A

New e-prescribing interface 2023 Treatment Timeline for Medical Study. Trial Name: NCT04310462 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor still have capacity for new participants?

"According to the clinicaltrials.gov data, this research is not presently enrolling subjects. This study was launched on February 1st 2017 and last modified on November 29th 2022. Despite this inactivity, 44 other trials are currently open for participation as of now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine

2017. "Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04310462.